Omalizumab (Xolair) is now available for NHS patients as an add-on treatment for severe, persistent allergic asthma in adults, adolescents and children, says NICE.
This follows additional analyses and the submission of a patient access scheme (PAS) by the manufacturer Novartis to the Department of Health which makes the treatment more cost-effective. In previous draft recommendations in November 2012, NICE was unable to recommend the treatment.
Mindray was founded on the belief that every life is valuable. As expensive and complex technology still remains out of reach for the majority of people, we are striving to improve healthcare by developing and sharing medical technologies with the world.
University of Warwick
8th - 9th August 2025
Manchester, Etihad Stadium
11th September 2025
Stansted Radisson Blu
23rd September 2025
Brighton Centre, UK
29th - 30th September 2025
Ramada Plaza, Wrexham
13th October 2025
EICC, Edinburgh
16th - 18th November 2025
